162046-66-4, The synthetic route of 162046-66-4 has been constantly updated, and we look forward to future research findings.
With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.162046-66-4,4-(4-(tert-Butoxycarbonyl)piperazin-1-yl)benzoic acid,as a common compound, the synthetic route is as follows.
4- (4- (tert-Butoxycarbonyl) pirhoerazin-1-yl) benzoic acid (10 g, 32.64 mmol) was dissolved in anhydrous THF (200 mL) under nitrogen at O0C and BH3. THF (IM in THF, 65.3 mL, 65.3 mmol) was added over 15 min. The reaction was EPO maintained at this temperature and after 3 h a further portion of BH3-THF (IM in THF, 10 mL, 10 itimol) was added. After 2 h, MeOH (30 mL) was added and the reaction was warmed to rt. The reaction mixture was partitioned between EtOAc (150 mL) and brine (200 mL) . The aqueous layer was re-extracted with EtOAc (100 ruL) and the combined organics were washed with a saturated aqueous solution of NaHCXb (150 mL) and then dried (MgSO/j) and filtered. On concentration of the solution the title compound (8.57 g, 90%) precipitated as a white solid and was collected by filtration. 1H NMR (CDCl3) 1.51 (9H, s), 8.14 (4H, t) , 3.62 (4H, t) , 4.62 (2H, d) , 6.94 (2H, d) , 7.31 (2H, d) .
162046-66-4, The synthetic route of 162046-66-4 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; VERTEX PHARMACEUTICALS INCORPORATED; WO2007/27528; (2007); A2;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics